Methenamine Hippurate Tablets Market Report 2026

Methenamine Hippurate Tablets Market Overview

• Methenamine Hippurate Tablets market size has reached to $10.11 billion in 2025 • Expected to grow to $14.49 billion in 2030 at a compound annual growth rate (CAGR) of 7.5% • Growth Driver: Methenamine Hippurate Tablets Market Surges Amidst Escalating Cases Of Urinary Tract Infections • Market Trend: Collaborative Expansion Revolutionize The Methenamine Hippurate Market • North America was the largest region in 2025.

What Is Covered Under Methenamine Hippurate Tablets Market?

Methenamine Hippurate Tablets refer to a medication primarily used as an antimicrobial agent. It is used to prevent and treat urinary tract infections (UTIs) by creating an acidic environment in the urine, which inhibits bacterial growth. This medication is often prescribed for patients with recurrent UTIs to reduce the frequency of infections. The main types of methenamine hippurate tablets are 20 tablets or bottles and 6 tablets or bottles. The methenamine hippurate tablets are available to patients in the form of 20 tablets or a bottle. The distribution channels involved are hospital pharmacies, online pharmacies and retail pharmacies and applications include uncomplicated UTIs and healthcare-associated UTIs. The end users include hospitals, homecare, specialty clinics and others.

What Is The Methenamine Hippurate Tablets Market Growth Forecast?

The methenamine hippurate tablets market size is expected to see strong growth in the next few years. It will grow to $14.49 billion in 2030 at a compound annual growth rate (CAGR) of 7.5%. The growth in the forecast period can be attributed to increasing incidence of urinary tract infections, growing demand for outpatient and homecare treatment, technological advancements in tablet formulation, rising adoption of personalized medicine, expansion of online pharmacy channels. Major trends in the forecast period include rising prevalence of recurrent utis, growth in geriatric population, increasing preference for oral antimicrobial therapies, expansion of home healthcare services, emergence of personalized medication regimens.

Global Methenamine Hippurate Tablets Market Segmentation

1) By Type: 20 Tablets Or Bottle, 6 Tablets Or Bottle 2) By Distribution Channel: Hospital Pharmacy, Online Pharmacy, Retail Pharmacy 3) By Application: Uncomplicated UTIs, Healthcare-associated UTIs 4) By End User: Hospitals, Homecare, Specialty Clinics, Other End Users Subsegments: 1) By 20 Tablets per Bottle: Standard Packaging, Bulk Packaging Options 2) By 6 Tablets per Bottle: Standard Packaging, Sample Or Trial Packaging

What Are The Drivers Of The Methenamine Hippurate Tablets Market?

The rising cases of urinary tract infections (UTI) are expected to boost the growth of the methenamine hippurate tablets market going forward. Urinary tract infections are common diseases that occur when bacteria enter the urethra and infect the urinary tract, usually through the skin or rectum. Methenamine hippurate tablets are used to prevent or treat recurring urinary tract infections caused by specific bacteria. For instance, in October 2023, according to the National Health Service, a UK-based government department In the 2022-23 period, there were 147,285 admissions for urinary tract infections (UTIs) as the primary diagnosis. Of these, 56% (82,392) were individuals aged 65 and older, with the largest number of admissions occurring in the 80-84 age group, which accounted for 17,280 admissions. Therefore, rising cases of urinary tract infections are driving the growth of the methenamine hippurate market. The rising healthcare expenditure is expected to propel the growth of the methenamine hippurate tablets market going forward. Healthcare expenditure refers to the total amount of financial resources spent on healthcare services, including medical treatments, hospital care, medications, and public health initiatives, by governments, businesses, and individuals. The increasing demand for healthcare expenditure is due to the rising prevalence of chronic diseases, which require long-term and costly treatments. Rising healthcare expenditure enhances methenamine hippurate tablet utilization by increasing access to urinary antiseptic treatments, making them more available for patients with recurrent urinary tract infections. Higher spending supports better diagnostic services and timely prescriptions, improving treatment efficiency and overall patient outcomes. For instance, in May 2024, according to the Office for National Statistics, a UK-based government department, total healthcare expenditure saw a 5.6% increase in nominal terms in 2023, an increase of 0.9% growth compared to 2022. Therefore, the rising healthcare expenditure is driving the growth of the methenamine hippurate tablets industry.

Key Players In The Global Methenamine Hippurate Tablets Market

Major companies operating in the methenamine hippurate tablets market are Alvogen Lux Holdings S.ÀR.L., Micro Labs Inc., Aurobindo Pharma, Amneal Pharmaceuticals Inc., Viatris Inc., Sun Pharmaceutical Industries Ltd., Cipla Ltd., Dr. Reddy's Laboratories Ltd., Cadila Healthcare Ltd., Torrent Pharmaceuticals Ltd., Glenmark Pharmaceuticals Ltd., Zydus Pharmaceuticals Ltd., Lupin Ltd., Alkem Laboratories Ltd., Ipca Laboratories Ltd., Granules India Ltd., Teva Pharmaceutical Industries Ltd., Apotex Pharmachem Inc., Sandoz International GmbH, Mylan Laboratories Ltd.

Global Methenamine Hippurate Tablets Market Trends and Insights

Major companies operating in the methenamine hippurate tablets market are making collaborations to increase their profitability in the market. Strategic collaboration is a purposeful partnership between entities to achieve mutual goals through coordinated efforts, leveraging each other’s strengths and resources. For instance, in May 2023, EQL Pharma AB, a Sweden-based pharmaceutical company that provides methenamine hippurate tablets, collaborated with Dr. Pfleger Arzneimittel GmbH. Through this collaboration, EQL Pharma AB aims to launch Methenamine Hippurate with an EQL-registered brand within the next two years with standard license fees, regulatory and reimbursement milestones, and a volume-dependent supply price with regulatory approval. Dr. Pfleger Arzneimittel GmbH is a Germany based pharmaceutical company.

Regional Insights

North America was the largest region in the methenamine hippurate tablets market in 2025. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Methenamine Hippurate Tablets Market?

The methenamine hippurate tablets market consists of sales of hexamine hippurate tablets, hiprex tablets, and urinary tract infection tablets. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Methenamine Hippurate Tablets Market Report 2026?

The methenamine hippurate tablets market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the methenamine hippurate tablets industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.